CSPG4 Antibody Detection of Tumor-Derived Exosomes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively detect and purify tumor-cell derived exosomes, which are key players in cancer cells' escape from immune surveillance, hindering the success of immunotherapy.
Innovation Solution
A method involving the use of antibodies or antigen-binding fragments that specifically bind chondroitin sulphate proteoglycan 4 (CSPG4) to detect and isolate tumor-cell derived exosomes from patient samples, utilizing techniques like ultrafiltration, differential centrifugation, and size exclusion chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then general detectability is maintained, but tumor-cell derived exosomes cannot be specifically detected or purified
Solution Approach 1:
The patent uses CSPG4-specific antibodies as intermediary molecules to bridge the detection system and tumor-cell derived exosomes. These antibodies specifically bind to CSPG4 markers on the exosome surface, enabling selective detection and purification without requiring direct interaction between the detection system and the exosomes themselves.
Solution Approach 2:
The patent extracts and isolates tumor-cell derived exosomes from complex biological samples by exploiting their unique CSPG4 marker expression. This extraction approach separates the target exosomes from other cellular components and exosome subpopulations, achieving specific purification.
2Reliability
If tumor-cell derived exosomes are not detected, then general monitoring continues, but immunotherapy response cannot be predicted
Solution Approach 1:
The patent replaces complex mechanical separation methods with immunological recognition systems. Instead of relying on physical properties for separation, the system uses antibody-antigen binding specificity to identify and isolate tumor-cell derived exosomes, simplifying the detection process while improving reliability.
3Manufacturing precision
If exosomes are not purified, then sample processing is simpler, but monitoring treatment response is compromised
Solution Approach 1:
The patent employs CSPG4-specific antibodies as intermediary agents that facilitate both detection and purification simultaneously. This dual-function approach allows for high-quality purification without requiring separate complex processing steps, maintaining productivity while achieving precise isolation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification of patients likely to benefit from immunotherapy by detecting the presence of tumor-cell derived exosomes, potentially resisting immune detection, and allows for the purification of these exosomes, aiding in monitoring treatment response.
Implementation Method 1
contacting a sample obtained from the patient with an antibody, an antigen-binding fragment thereof, or a ligand that specifically binds chondroitin sulphate proteoglycan 4 (CSPG4)
Implementation Method 2
utilizing techniques like ultrafiltration, differential centrifugation, and size exclusion chromatography
Implementation Method 3
utilizing techniques like ultrafiltration, differential centrifugation, and size exclusion chromatography
Data Source
AI summary
The disclosure features compositions and methods that may be used to detect the presence of tumor cell-derived exosomes in a patient (e.g., a human patient) having cancer. The compositions and methods described herein may also be used to evaluate the patient's prognosis, as well as monitor the likelihood of the patient to benefit from therapy, such as immunotherapy. The disclosure also features antibodies that specifically bind chondroitin sulphate proteoglycan 4 (CSPG4), as well as antigen-antibody complexes containing the same.